Passage Bio, Inc. filed an 8-K on November 18, 2026, disclosing that it received a Nasdaq deficiency letter on November 12, 2026, for failing to meet the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market.
Key Highlights
- Deficiency notice received: Passage Bio received a letter from Nasdaq's Listing Qualifications Department on November 12, 2026, citing non-compliance with Nasdaq Listing Rule 5550(b)(1).
- Stockholders' equity of $50,000: As of its Quarterly Report for the quarter ended September 30, 2026, Passage Bio reported stockholders' equity of $50,000, well below the required minimum of $2,500,000.
- Alternatives not met: According to the filing, as of November 12, 2026, Passage Bio also did not meet the alternatives of market value of listed securities or net income from continuing operations.
- No immediate listing impact: The filing states the letter "has no immediate effect on the listing of the Company's common stock," which continues to trade on the Nasdaq Capital Market under NASDAQ:PASG.
- Pending merger with Remix Therapeutics: Passage Bio expects to complete its previously announced mergers with Remix Therapeutics, Inc. under an Amended and Restated Agreement and Plan of Merger dated September 2, 2026, as amended on October 5, 2026.
- Name and ticker change anticipated: Upon closing of the mergers, the company expects to change its name to "Remix Therapeutics, Inc." and begin trading under the symbol "RMTX."
- Compliance path identified: The company disclosed it believes completion of the mergers and related transactions will restore compliance with Nasdaq's minimum stockholders' equity requirement.
Passage Bio Discloses Nasdaq Equity Deficiency and Merger-Based Compliance Plan
According to the filing, Passage Bio received a formal deficiency letter from Nasdaq on November 12, 2026, notifying the company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1). That rule requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders' equity. Passage Bio reported stockholders' equity of $50,000 in its Form 10-Q for the quarter ended September 30, 2026, and the filing states the company did not meet either of the two alternative compliance standards as of the date of the letter.
The company disclosed that its primary plan for regaining compliance centers on the pending mergers with Remix Therapeutics, Inc. The mergers are governed by an Amended and Restated Agreement and Plan of Merger dated September 2, 2026, and subsequently amended on October 5, 2026. The structure involves the merger of Peregrine Merger Sub, Inc. with and into Remix, with Remix surviving as a wholly owned subsidiary of Passage Bio, followed by a subsequent merger into Peregrine Merger Sub II, LLC. The company stated the mergers are expected to close "as promptly as practicable" following satisfaction or waiver of remaining closing conditions, including Nasdaq approval of the listing of the combined company's common stock.
The filing notes that if the mergers are not completed within the period provided under Nasdaq Listing Rules, Passage Bio intends to submit a plan to regain compliance. The company referenced its registration statement on Form S-4, filed July 21, 2026, most recently amended October 8, 2026, and declared effective by the SEC on October 9, 2026, for further information. The filing was signed by Kathleen Borthwick, Chief Financial Officer, on November 18, 2026. Statements regarding timing of the mergers and compliance recovery are characterized in the filing as forward-looking statements subject to risks and uncertainties.
What Was Disclosed
Passage Bio filed an 8-K reporting a Nasdaq deficiency notice tied to stockholders' equity of $50,000, below the $2,500,000 minimum. The company disclosed a pending merger with Remix Therapeutics as its expected path to restoring compliance, with a potential name and ticker change upon closing.





Please wait processing your request...